TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: transmedics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/21/2024 | $208.00 | Buy | Needham |
6/6/2024 | $161.00 | Overweight | Cantor Fitzgerald |
6/4/2024 | $151.00 | Overweight | Stephens |
3/28/2024 | $95.00 | Overweight | Piper Sandler |
7/19/2023 | Outperform | Robert W. Baird | |
8/2/2022 | $48.00 | Neutral → Overweight | JP Morgan |
2/25/2022 | $22.00 → $15.00 | Equal-Weight | Morgan Stanley |
1/7/2022 | $33.00 → $22.00 | Equal-Weight | Morgan Stanley |
144 - TransMedics Group, Inc. (0001756262) (Subject)
144 - TransMedics Group, Inc. (0001756262) (Subject)
144 - TransMedics Group, Inc. (0001756262) (Subject)
10-Q - TransMedics Group, Inc. (0001756262) (Filer)
144 - TransMedics Group, Inc. (0001756262) (Subject)
8-K - TransMedics Group, Inc. (0001756262) (Filer)
8-K - TransMedics Group, Inc. (0001756262) (Filer)
8-K - TransMedics Group, Inc. (0001756262) (Filer)
SD - TransMedics Group, Inc. (0001756262) (Filer)
8-K - TransMedics Group, Inc. (0001756262) (Filer)
ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time. Event: Morgan Stanley 22nd Annual Global Healthcare Confere
ANDOVER, Mass., Aug. 20, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 16, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 3,073 shares of its common stock and an aggregate of 2,003 restricted stock units to 4 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4)
ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023Generated net income of $12.2 million or $0.35 per diluted share in the second quarter of 2024Owned 15 total aircraft as of June 30, 2024Purc
ANDOVER, Mass., July 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Tuesday, August 13, 2024, at 9:30 a.m. Eastern Standard Time. Event: Canaccord Genuity 44th Annual Growth Conference Date: Tuesday, August 13,
ANDOVER, Mass., July 18, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 15, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,522 shares of its common stock and an aggregate of 6,240 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) a
ANDOVER, Mass., July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for dome
ANDOVER, Mass., June 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 18, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 1,002 shares of its common stock and an aggregate of 657 restricted stock units to 1 employee, each as a material inducement for the employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and p
ANDOVER, Mass., May 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 18,320 shares of its common stock and an aggregate of 12,068 restricted stock units to 8 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) a
ANDOVER, Mass., April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023Generated net income of $12.2 million or $0.35 per fully diluted share in the first quarter of 2024OCS Heart and OCS Lung and associated new cli
ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domes
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
4 - TransMedics Group, Inc. (0001756262) (Issuer)
ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be
ANDOVER, Mass., Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. "Nick has extensive end-to-end supply chain and operations experience making him the perfect fit for TransMedics as we expand our operations to meet the growing global demand for OCS products and service," said Waleed H
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta
Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in
ANDOVER, Mass., Dec. 23, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Merilee Raines to its Board of Directors and as a member of the Audit Committee, effective January 1, 2021. The Board appointed Ms. Raines as Chair of the Audit Committee, effective as of June 1, 2021. Ms. Raines brings over 30 years of executive management and board experience. Through her career she served in multiple roles of increasing responsibility at IDEXX Laboratories, Inc. and currently sits on the Boards of Dir
ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023Generated net income of $12.2 million or $0.35 per diluted share in the second quarter of 2024Owned 15 total aircraft as of June 30, 2024Purc
ANDOVER, Mass., July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for dome
ANDOVER, Mass., April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023Generated net income of $12.2 million or $0.35 per fully diluted share in the first quarter of 2024OCS Heart and OCS Lung and associated new cli
ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domes
ANDOVER, Mass., Feb. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022Generated net income o
ANDOVER, Mass., Feb. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2023 after market close on Monday, February 26, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 80
ANDOVER, Mass., Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2023. Recent Highlights Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second quarter of 2022.Transplant centers' use of the National OCS Program (NOP) drove approximately 93% of total U.S. OCS cases.Signed definitive agreement to acquire
ANDOVER, Mass., Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that is has acquired from Bridge to Life Ltd. ("Bridge to Life"), assets and intellectual property related to the Ex-Vivo Organ Support System ("EVOSS") and LifeCradle Heart Preservation Transport System ("LifeCradle") technologies. EVOSS is a warm perfusion technology designed for lung and heart transplantation and LifeCradle is a cold perfusion technology designed for heart transplantation. TransMedics intends to further develop these technolo
ANDOVER, Mass., July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2023 after market close on Thursday, August 3, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for dome
ANDOVER, Mass., May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights Net revenue of $41.6 million in the first quarter of 2023, a 162% increase compared to the first quarter of 2022Transplant centers' use of the National OCS Program (NOP) drove approximately 91% of total U.S. OCS casesPublished Inaugural Environmental, Social,
Needham initiated coverage of TransMedics Group with a rating of Buy and set a new price target of $208.00
Cantor Fitzgerald initiated coverage of TransMedics Group with a rating of Overweight and set a new price target of $161.00
Stephens initiated coverage of TransMedics Group with a rating of Overweight and set a new price target of $151.00
Piper Sandler initiated coverage of TransMedics Group with a rating of Overweight and set a new price target of $95.00
Robert W. Baird initiated coverage of TransMedics Group with a rating of Outperform
JP Morgan upgraded TransMedics Group from Neutral to Overweight and set a new price target of $48.00
Morgan Stanley reiterated coverage of TransMedics Group with a rating of Equal-Weight and set a new price target of $15.00 from $22.00 previously
Morgan Stanley reiterated coverage of TransMedics Group with a rating of Equal-Weight and set a new price target of $22.00 from $33.00 previously
Morgan Stanley reiterated coverage of TransMedics Group with a rating of Equal-Weight and set a new price target of $35.00 from $38.00 previously
Canaccord Genuity reiterated coverage of TransMedics Group with a rating of Buy and set a new price target of $79.00 from $46.00 previously
TransMedics Gr (NASDAQ:TMDX) has outperformed the market over the past 5 years by 30.55% on an annualized basis producing an average annual return of 43.06%. Currently, TransMedics Gr has a market capitalization of $5.09 billion. Buying $1000 In TMDX: If an investor had bought $1000 of TMDX stock 5 years ago, it would be worth $5,892.80 today based on a price of $154.60 for TMDX at the time of writing. TransMedics Gr's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated con
TransMedics Gr (NASDAQ:TMDX) has outperformed the market over the past 5 years by 27.68% on an annualized basis producing an average annual return of 41.28%. Currently, TransMedics Gr has a market capitalization of $4.75 billion. Buying $100 In TMDX: If an investor had bought $100 of TMDX stock 5 years ago, it would be worth $587.32 today based on a price of $144.09 for TMDX at the time of writing. TransMedics Gr's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content
Morgan Stanley analyst Patrick Wood maintains TransMedics Gr (NASDAQ:TMDX) with a Equal-Weight and raises the price target from $104 to $145.
In the last three months, 9 analysts have published ratings on TransMedics Gr (NASDAQ:TMDX), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 6 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 1 0 0 0 3M Ago 2 3 0 0 0 Analysts have recently evaluated TransMedics Gr and provided 12-month price targets. The average target is $137.22, accompanied by a high estimate of $175.00 and a low estimate of $117.00. Witnessing a positive sh
Piper Sandler analyst Matt O'Brien maintains TransMedics Gr (NASDAQ:TMDX) with a Overweight and raises the price target from $120 to $170.
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of
TransMedics Gr's (NYSE:TMDX) short percent of float has risen 3.74% since its last report. The company recently reported that it has 5.98 million shares sold short, which is 22.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.86 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
In the preceding three months, 9 analysts have released ratings for TransMedics Gr (NASDAQ:TMDX), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 6 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 1 0 0 0 2M Ago 2 3 0 0 0 3M Ago 0 1 0 0 0 Analysts have recently evaluated TransMedics Gr and provided 12-month price targets. The average target is $128.89, accompanied by a high estimate of $175.00 and a low estimate of $95.00. Observing a 19.19% i
Piper Sandler analyst Matt O'Brien maintains TransMedics Gr (NASDAQ:TMDX) with a Overweight and maintains $120 price target.
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Applied Therapeutics Inc (NASDAQ:APLT) On May 9, Applied Therapeutics posted downbeat quarte